PDCD1 and nonpapillary renal cell carcinoma: Nivolumab is a programmed death 1 (PD-1) inhibitor, and its combination with ipilimumab (cytotoxic T lymphocyte associated antigen-4 inhibitor) is superior to sunitinib in terms of OS and objective response rates in the treatment of patients with advanced ccRCC (36–39).